Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 10, 23 | -0.57 Increased by +13.64% | -0.58 Increased by +2.97% |
| Mar 28, 23 | -0.52 Increased by +32.47% | -0.71 Increased by +37.69% |
| Nov 9, 22 | -0.68 Increased by +50.00% | -0.74 Increased by +10.96% |
| Aug 10, 22 | -0.87 Increased by +35.56% | -0.75 Decreased by -21.33% |
| May 12, 22 | -0.66 Increased by +51.11% | -0.71 Increased by +9.92% |
| Mar 17, 22 | -0.77 Increased by +48.67% | -0.98 Increased by +21.87% |
| Nov 10, 21 | -1.36 Increased by +24.44% | -0.66 Decreased by -160.70% |
| Aug 11, 21 | -1.35 Increased by +18.18% | -6.00 Increased by +12.92% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 5.87 M Increased by +154.31% | -13.68 M Increased by +1.59% | Decreased by -233.15% Increased by +61.30% |
| Dec 31, 22 | 5.23 M Increased by +422.70% | -13.91 M Increased by +13.30% | Decreased by -266.16% Increased by +83.41% |
| Sep 30, 22 | 4.25 M Increased by +N/A% | -13.32 M Increased by +84.71% | Decreased by -313.76% Decreased by N/A% |
| Jun 30, 22 | 3.44 M Increased by +N/A% | -18.27 M Decreased by -314.46% | Decreased by -531.54% Decreased by N/A% |
| Mar 31, 22 | 2.31 M Increased by +N/A% | -13.90 M Decreased by -212.94% | Decreased by -602.51% Decreased by N/A% |
| Dec 31, 21 | 1.00 M Decreased by -92.86% | -16.05 M Decreased by -240.15% | Decreased by -1.60 K% Decreased by -4.66 K% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -87.09 M Decreased by -1.66 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by -100.00% | -4.41 M Decreased by -147.52% | Decreased by N/A% Decreased by N/A% |
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.